Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. DAWN
stocks logo

DAWN

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
35.55M
+334.01%
-0.345
+590.96%
40.00M
-57.33%
-0.327
-186.09%
--
--
-0.326
-48.29%
Estimates Revision
The market is revising Downward the revenue expectations for Day One Biopharmaceuticals, Inc. (DAWN) for FY2025, with the revenue forecasts being adjusted by -5.39% over the past three months. During the same period, the stock price has changed by -1.19%.
Revenue Estimates for FY2025
Revise Downward
down Image
-5.39%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-12.06%
In Past 3 Month
Stock Price
Go Down
down Image
-1.19%
In Past 3 Month
8 Analyst Rating
up Image0
Wall Street analysts forecast DAWN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DAWN is 28.14 USD with a low forecast of 20.00 USD and a high forecast of 36.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
1 Hold
0 Sell
Strong Buy
up Image0
Current: 6.630
sliders
Low
20.00
Averages
28.14
High
36.00
up Image0
Current: 6.630
sliders
Low
20.00
Averages
28.14
High
36.00
HC Wainwright & Co.
Andres Maldonado
Strong Buy
Reiterates
$36
2025-04-03
Reason
HC Wainwright & Co.
Andres Maldonado
Price Target
$36
2025-04-03
Reiterates
Strong Buy
Reason
Goldman Sachs
Andrea Tan
Strong Buy
Maintains
$39 → $27
2025-03-25
Reason
Goldman Sachs
Andrea Tan
Price Target
$39 → $27
2025-03-25
Maintains
Strong Buy
Reason
JP Morgan
Anupam Rama
Buy
Maintains
$39 → $34
2025-03-05
Reason
JP Morgan
Anupam Rama
Price Target
$39 → $34
2025-03-05
Maintains
Buy
Reason
JPMorgan analyst Anupam Rama lowered the firm's price target on Day One Biopharmaceuticals to $34 from $39 and keeps an Overweight rating on the shares. The firm updated models in the Smid-cap biotechnology group.
Needham
Ami Fadia
Strong Buy
Reiterates
$32
2025-02-26
Reason
Needham
Ami Fadia
Price Target
$32
2025-02-26
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Andres Maldonado
Strong Buy
Maintains
$40 → $36
2025-02-26
Reason
HC Wainwright & Co.
Andres Maldonado
Price Target
$40 → $36
2025-02-26
Maintains
Strong Buy
Reason
Wedbush
Robert Driscoll
Buy
Reiterates
$32
2025-02-26
Reason
Wedbush
Robert Driscoll
Price Target
$32
2025-02-26
Reiterates
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Day One Biopharmaceuticals Inc (DAWN.O) is -5.28, compared to its 5-year average forward P/E of -8.13. For a more detailed relative valuation and DCF analysis to assess Day One Biopharmaceuticals Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-8.13
Current PE
-5.28
Overvalued PE
-4.72
Undervalued PE
-11.53

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-5.49
Current EV/EBITDA
-1.39
Overvalued EV/EBITDA
-1.03
Undervalued EV/EBITDA
-9.95

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
526.47
Current PS
3.89
Overvalued PS
2463.63
Undervalued PS
-1410.69

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

DAWN News & Events

Events Timeline

(ET)
2025-06-10
08:40:57
Day One Biopharmaceuticals appoints Michael Vasconcelles as Head of R&D
select
2025-05-06 (ET)
2025-05-06
16:18:25
Day One Biopharmaceuticals reports Q1 EPS (35c), consensus (44c)
select
2025-02-25 (ET)
2025-02-25
16:20:45
Day One Biopharmaceuticals reports Q4 EPS ($1.02), consensus (35c)
select
Sign Up For More Events
Sign Up For More Events

News

Preview
3.0
07-07NASDAQ.COM
DAY ONE BIOPHARMACEUTICALS Earnings Preview: Recent $DAWN Insider Trading, Hedge Fund Activity, and More

  • Earnings Release Anticipation: DAY ONE BIOPHARMACEUTICALS is set to announce its quarterly earnings on July 8th, with analysts predicting revenue of approximately $36.6 million and a loss of $0.36 per share.

  • Insider Trading Activity: In the past six months, insiders have sold $DAWN stock seven times without any purchases, while 106 institutional investors increased their holdings and 65 reduced theirs in the last quarter.

Preview
5.0
06-10Newsfilter
Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development

  • New Leadership Appointment: Dr. Michael Vasconcelles has joined Day One Biopharmaceuticals as Head of Research & Development, bringing over 25 years of experience in oncology and health technology to enhance the company's pipeline and growth strategies.

  • Company Mission: Day One Biopharmaceuticals aims to address the unmet needs in pediatric cancer treatment by developing targeted therapies for patients of all ages, emphasizing a commitment to scientific excellence and transformative medicine.

Preview
3.0
05-05Yahoo Finance
Day One Biopharmaceuticals Inc (DAWN) Q1 2025 Earnings Report Preview: What to Expect

  • Earnings Release and Estimates: Day One Biopharmaceuticals Inc (NASDAQ:DAWN) is set to release its Q1 2025 earnings on May 6, with expected revenue of $30.24 million and a loss of -$0.44 per share. Full-year revenue estimates have declined from $164.92 million to $155.91 million for 2025.

  • Analyst Ratings and Price Targets: The average target price for DAWN is $29.00, indicating a potential upside of 265.70% from the current price of $7.93, despite GuruFocus estimating a GF Value of $0, suggesting a downside of -100%. The consensus recommendation from brokerage firms indicates an "Outperform" status.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Day One Biopharmaceuticals Inc (DAWN) stock price today?

The current price of DAWN is 6.63 USD — it has decreased -2.5 % in the last trading day.

arrow icon

What is Day One Biopharmaceuticals Inc (DAWN)'s business?

Day One Biopharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing targeted therapies for people of all ages with life-threatening diseases. The Company partners with clinical oncologists, families, and scientists to identify, acquire, and develop cancer treatments. The Company’s commercial product, OJEMDA (tovorafenib), is an oral, brain-penetrant, selective type II rapidly accelerated fibrosarcoma (RAF) kinase inhibitor of mutant BRAF V600, wild-type BRAF, and wild-type CRAF kinases. Its pipeline product candidates include DAY301 and VRK1 program. The DAY301 candidate is a PTK7 targeted ADC composed of a novel humanized anti-PTK7 immunoglobulin G1 monoclonal antibody (mAb), conjugated with a topoisomerase I inhibitor through a stable and hydrophilic modified valine-alanine (VA) cleavable linker. Its VRK1 program is a novel target involved in the regulation of cell division and DNA damage repair.

arrow icon

What is the price predicton of DAWN Stock?

Wall Street analysts forecast DAWN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DAWN is 28.14 USD with a low forecast of 20.00 USD and a high forecast of 36.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Day One Biopharmaceuticals Inc (DAWN)'s revenue for the last quarter?

Day One Biopharmaceuticals Inc revenue for the last quarter amounts to 30.76M USD, decreased % YoY.

arrow icon

What is Day One Biopharmaceuticals Inc (DAWN)'s earnings per share (EPS) for the last quarter?

Day One Biopharmaceuticals Inc. EPS for the last quarter amounts to -0.35 USD, decreased -51.39 % YoY.

arrow icon

What changes have occurred in the market's expectations for Day One Biopharmaceuticals Inc (DAWN)'s fundamentals?

The market is revising Downward the revenue expectations for Day One Biopharmaceuticals, Inc. (DAWN) for FY2025, with the revenue forecasts being adjusted by -5.39% over the past three months. During the same period, the stock price has changed by -1.19%.
arrow icon

How many employees does Day One Biopharmaceuticals Inc (DAWN). have?

Day One Biopharmaceuticals Inc (DAWN) has 181 emplpoyees as of July 08 2025.

arrow icon

What is Day One Biopharmaceuticals Inc (DAWN) market cap?

Today DAWN has the market capitalization of 672.03M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free